CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,557 | $69.40 | $247K | 608,983 |
| 2026-06-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −8,149 | $70.50 | $575K | 600,834 |
| 2026-06-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,294 | $71.38 | $235K | 597,540 |
| 2026-06-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 105,494 |
| 2026-06-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −1,801 | $69.75 | $126K | 103,693 |
| 2026-06-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −2,599 | $70.77 | $184K | 101,094 |
| 2026-06-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −3,100 | $72.06 | $223K | 97,994 |
| 2026-06-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 374,857 | ||
| 2026-05-27 | Milligan Sandra Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-27 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-27 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-27 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-27 | Stelzer Laurie Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-27 | McKenna Mark C. Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −2,404 | $72.57 | $174K | 166,202 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −33,513 | $73.72 | $2.5M | 132,689 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −24,814 | $74.76 | $1.9M | 107,875 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −19,269 | $75.35 | $1.5M | 88,606 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Option exercise 10b5-1 | +78,333 | $27.46 | $2.2M | 78,333 |
| 2026-05-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −21,306 | $69.53 | $1.5M | 57,027 |
Page 5 of 11 · 213 trades